Effects of acute, subchronic and intermittent MDMA ('ecstasy') administration on agonistic interactions between male mice

Aggressive Behavior

Volumn 30, Issue 1, 2004, Pages 84-91

  Navarro, José Francisco ^a   Maldonado, Enrique ^a  

^a UNIVERSITY OF MÁLAGA   (Spain)

Author keywords

Aggression; Anxiety; MDMA; Mice

Indexed keywords

EID: 1642444562     PISSN: 0096140X     EISSN: None     Source Type: Journal    
DOI: 10.1002/ab.20004     Document Type: Article

References (31)

1. Bankson MG, Cunningham KA. 2001. 3,4-Methylenedioxymethamphetamine (MDMA) as a unique model of serotonin receptor function and serotonin-dopamine interactions. J Pharmacol Exp Ther 297:846-852.
2. Bathacharya SK, Bathacharya A, Glosal S. 1998. Anxiogenic activity of methylenedioxymethamphetamine (Ecstasy): an experimental study. Biol Amines 14:217-237.
3. Bathacharya S, Powell JH. 2001. Recreational use of 3,4-methylenedioxymethamphetamine (MDMA) or 'ecstasy': evidence for cognitive impairment. Psychol Med 31:647-658.
4. Boot BP, McGregor IS, Hall W. 2000. MDMA (Ecstasy) neurotoxicity: assessing and communicating the risks. Lancet 355:1818-1821.
5. Brain PF, Benton D, Childs G, Parmigiani S. 1981. The effect of the opponent in tests of murine aggression. Behav Processes 6:319-328.
6. Brain PF, McAllister KH, Walmsley S. 1989. Drug effects on social behavior. Methods in ethopharmacology. In: Boulton AA, Baker GB, Greenshaw AJ, editors. Neuromethods. Vol. 13. Psychopharmacology. Clifton, New Jersey: The Humana Press, pp 687-739.
7. Broocks A, Briggs NC, Pigott TA, Hill JL, Canter SK, Tolliver TJ, Baldemore D, Murphy DL. 1997. Behavioral, physiological and neuroendocrine responses in healthy volunteers to m-chlorophenylpiperazine (m-CPP) with and without ondansetron pretreatment. Psychopharmacology 130:91-103.
8. Curran HV. 2000. Is MDMA ('Ecstasy') neurotoxic in humans? An overview of evidence and of methodological problems in research. Neuropsychobiol 42:34-41.
9. Fischer C, Hatzidimitfiou G, Wlos J, Katz J, Ricaurte G. 1995. Reorganization of ascending 5-HT axon projections in animals previously exposed to the recreational drug 3,4-Methylenedioxymethampheta mine (MDMA, 'ecstasy'). J Neurosci 15:5426-5485.
10. Gudelsky GA, Nash JF. 1996. Carrier-mediated release of serotonin by 3,4-methylenedioxymethamphetamine: implications for serotonin-dopamine interactions. J Neurochem 66:243-249.
11. Koch S, Galloway MP. 1997. MDMA induced dopamine release in vivo: role of endogenous serotonin. J Neural Transm 104:135-146.
12. Liechti ME, Gamma A, Vollenweider FX. 2001. Gender differences in the subjective effects of MDMA. Psychopharmacology 154:161-168.
13. Lin HQ, Burden PM, Chriestie MJ, Johnson GAR. 1999. The anxiogenic-like and anxiolytic-like effects of MDMA on mice in the elevated plus-maze: a comparison with amphetamine. Pharmacol Biochem Behav 1999;62:403-408.
14. Maldonado E, Navarro JF. 2000. Effects of 3,4-methylenedioxymethamphetamine (MDMA) on anxiety in mice tested in the light-dark box. Prog NeuroPsychopharmacol Biol Psychiat 24:463-472.
15. Maldonado E, Navarro JF, Romero C, Martin M, Beltrán D. 2000. Acute and subchronic effects of MDMA on anxiety in the "elevated plus maze test" in male mice. Eur Neuropsychopharmacol 10 (suppl): S342.
16. Maldonado E, Navarro JF. 2001. MDMA ('ecstasy') exhibits anxiogenic-like activity in social encounters between male mice. Pharmacol Res 44:27-31.
17. McCann UD, Eligulashvili V, Ricaurte GA. 2000. (± )3,4-Methylenedioxymethamphetamie ('Ecstasy')-induced serotonin neurotoxicity: clinical studies. Neuropsychobiol 42:11-16.
18. Meert TF, Melis W, Alerts N, Clincke G. 1997. Antagonism of metachlorophenylpiperazine-induced inhibition of exploratory activity in an emergence procedure, the open field test, in rats. Behav Pharmacol 8:353-363.
19. Miczek KA, Haney M. 1994. Psychomotor stimulant effects of d-amphetamine, MDMA and PCP: aggressive and schedule-controlled behavior in mice. Psychopharmacology 115:358-365.
20. Morgan MJ. 2000. Ecstasy (MDMA): a review of its possible persistent psychological effects. Psychopharmacology 152:230-248.
21. Morlay KC, McGregor IS. 2000. (± )-3,4-Methylenedioxymethamphetamine (MDMA, 'Ecstasy') increases social interaction in rats. Eur J Pharmacol 408:41-49.
22. Moro M, Salvador A, Simón VM. 1997. Effects of repeated administration of d-amphetamine on agonistic behavior of isolated male mice. Behav Pharmacol 8:309-318.
23. Navarro JF. 1997. An ethopharmacological analysis of the agonistic interactions in isolated male mice: comparison between OF. 1 and NMRI strains. Psicothema 9:333-336.
24. Navarro JF, Maldonado E. 1999. Behavioral profile of 3,4-methylenedioxymethamphetamine (MDMA) in agonistic encounters between male mice. Prog NeuroPsychopharmacol Biol Psychiat 23:327-334.
25. Ricaurte GA, Yuan J, McCann UD. 2000. (± )3,4-Methylenedioxymethamphetamine ('Ecstasy')-induced serotonin neurotoxicity: studies in animals. Neuropsychobiol 42:5-10.
26. Rodgers J. 2000. Cognitive performance amongst recreational users of "ecstasy". Psychopharmacology 151:19-24.
27. Steele TD, McCann UD, Ricaurte GA. 1994. 3,4-methylenedioxymethamphetamine (MDMA): pharmacology and toxicology in animals and humans. Addiction 89:539-551.
28. Stephenson CP, Hunt GE, Topple AN, McGregor IS. 1999. The distribution of 3,4-methylenedioxymethamphetamine-induced c-fos expression in rat brain. Neuroscience 92:1011-1023.
29. Topp L, Hando J, Dillon P, Roche A, Solowij N. 1999. Ecstasy use in Australia: patterns of use and associated harm. Drug Alcohol Depend 55: 105-115.
30. Valzelli L. 1969. Aggressive behavior induced by isolation. In: Garrattini S, Sigg EB, editors. Aggressive behavior. Amsterdam: Excerpta Medica, pp. 70-76.
31. Vollenweider FX, Gamma A, Liechti M, Huber T. 1998. Psychological and cardiovascular effects and short-term sequelae of MDMA ('Ecstasy') in MDMA-naive healthy volunteers. Neuropsychopharmacology 19:241-251.